What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008.
Rosovsky
Rachel P
RP
Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Crowther
Mark A
MA
D000925:Anticoagulants / Q000037:antagonists & inhibitors*; D015942:Factor VIIa / Q000627:therapeutic use*; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve; D011994:Recombinant Proteins / Q000627:therapeutic use; D012196:Review Literature as Topic; D012449:Safety; D012769:Shock / Q000139:chemically induced / Q000188:drug therapy; D014859:Warfarin / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D011994:Recombinant Proteins; D014859:Warfarin; C103587:recombinant FVIIa; D015942:Factor VIIa